The CAncer Prostate Consortium of India (CAPCI) was virtually started in 2016 by a group of researchers and clinicians interested in identifying inherited and somatic risk factors that are related to theonset of prostate cancer (PCa). The consortium aims to improve the patient care and treatment in India byexploring and expanding the utility of genomic repositories associated with PCa. These aims are reached by advancing discovery in genome science particular to Indian phenotypes, translating scientific discoveries to improved standard of care. One of the impending goals of the consortium is to combine the data from the west and other sub-population ancestries, and identify common and exclusive risk profiles associated with PCa in Indian scenarios. These findings would additionally allow us to validate in experimental settings to explore the molecular mechanisms underlying pathogenesis of PCa besides understanding new personalized therapeutic regimens..
Founder and PI: Prashanth N Suravajhala
Adviser-in-Chief: Nirmal K Lohiya
Other members: Nidhi Shukla, AS Ansari, Gyaneshwer Chaubey, Renuka Suravajhala, Krishna Mohan Medicherla, Shatrunjai Giri
Clinicians: Devendra Sharma, TS Sadasukhi, Nripesh Sadasukhi, Maneesh Vijay, Gaurav, Jalendra
Postdoc: Barkha Khilwani,
PhD fellow: Soham Biswas, Poonam Sen
Industrial members: Spandan Chaudhary, Neeraj Arora, Gopalakrishna Ramaswamy
International members: Rune Mathiessen, Rupert Ecker, Jyotsna Batra, Keshav K Singh
